Who are eye drops (Phenylephrin)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Doxazosin mysylate GITS, Bupivacaine-adrenaline, Comparator: carvedilol, Doxazosin (drug), Norepinephrine (Levophed), Arotinolol Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eye-drops-phenylephrin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

eye drops (Phenylephrin) — Competitive Intelligence Brief

eye drops (Phenylephrin) (eye drops (Phenylephrin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist. Area: Ophthalmology.

marketed Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

eye drops (Phenylephrin) (eye drops (Phenylephrin)) — Medical University of Graz. Phenylephrine is an alpha-1 adrenergic agonist that constricts blood vessels in the eye to reduce redness and dilate the pupil.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
eye drops (Phenylephrin) TARGET	eye drops (Phenylephrin)	Medical University of Graz	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Doxazosin mysylate GITS	Doxazosin mysylate GITS	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Bupivacaine-adrenaline	Bupivacaine-adrenaline	University of Aarhus	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)
Comparator: carvedilol	Comparator: carvedilol	Organon and Co	marketed	Beta-blocker with alpha-1 antagonist activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Doxazosin (drug)	Doxazosin (drug)	Japan Heart Foundation	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
Arotinolol Hydrochloride	Arotinolol Hydrochloride	Sumitomo Pharma (Suzhou) Co., Ltd.	marketed	Alpha-beta blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist class)

Allergan · 2 drugs in this class
EMS · 1 drug in this class
Institute of Liver and Biliary Sciences, India · 1 drug in this class
Medical University of Graz · 1 drug in this class
Rawalpindi Medical College · 1 drug in this class
Tehran Heart Center · 1 drug in this class
Actavis Inc. · 1 drug in this class
University Tunis El Manar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). eye drops (Phenylephrin) — Competitive Intelligence Brief. https://druglandscape.com/ci/eye-drops-phenylephrin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab